| Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial I Olivotto, A Oreziak, R Barriales-Villa, TP Abraham, A Masri, ... The Lancet 396 (10253), 759-769, 2020 | 1262 | 2020 |
| Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) CY Ho, SM Day, EA Ashley, M Michels, AC Pereira, D Jacoby, AL Cirino, ... Circulation 138 (14), 1387-1398, 2018 | 879 | 2018 |
| Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey) MS Maurer, M Hanna, M Grogan, A Dispenzieri, R Witteles, B Drachman, ... Journal of the American College of Cardiology 68 (2), 161-172, 2016 | 582 | 2016 |
| Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy ED Smith, NK Lakdawala, N Papoutsidakis, G Aubert, A Mazzanti, ... Circulation 141 (23), 1872-1884, 2020 | 470 | 2020 |
| Empagliflozin in heart failure: diuretic and cardiorenal effects M Griffin, VS Rao, J Ivey-Miranda, J Fleming, D Mahoney, C Maulion, ... Circulation 142 (11), 1028-1039, 2020 | 444 | 2020 |
| Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy CY Ho, ME Mealiffe, RG Bach, M Bhattacharya, L Choudhury, ... Journal of the American College of Cardiology 75 (21), 2649-2660, 2020 | 385 | 2020 |
| Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial SB Heitner, D Jacoby, SJ Lester, A Owens, A Wang, D Zhang, J Lambing, ... Annals of internal medicine 170 (11), 741-748, 2019 | 346 | 2019 |
| Machine learning prediction of mortality and hospitalization in heart failure with preserved ejection fraction S Angraal, BJ Mortazavi, A Gupta, R Khera, T Ahmad, NR Desai, ... JACC: Heart Failure 8 (1), 12-21, 2020 | 336 | 2020 |
| Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy CN Toepfer, AC Garfinkel, G Venturini, H Wakimoto, G Repetti, L Alamo, ... Circulation 141 (10), 828-842, 2020 | 330 | 2020 |
| Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy DP Judge, SB Heitner, RH Falk, MS Maurer, SJ Shah, RM Witteles, ... Journal of the American College of Cardiology 74 (3), 285-295, 2019 | 286 | 2019 |
| Genetics of inherited cardiomyopathy D Jacoby, WJ McKenna European heart journal 33 (3), 296-304, 2012 | 249 | 2012 |
| Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis S Saberi, N Cardim, M Yamani, J Schulz-Menger, W Li, V Florea, ... Circulation 143 (6), 606-608, 2021 | 245 | 2021 |
| Aficamten for symptomatic obstructive hypertrophic cardiomyopathy MS Maron, A Masri, ME Nassif, R Barriales-Villa, M Arad, N Cardim, ... New England Journal of Medicine 390 (20), 1849-1861, 2024 | 243 | 2024 |
| Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase … JA Spertus, JT Fine, P Elliott, CY Ho, I Olivotto, S Saberi, W Li, C Dolan, ... The Lancet 397 (10293), 2467-2475, 2021 | 236 | 2021 |
| Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry P Marstrand, L Han, SM Day, I Olivotto, EA Ashley, M Michels, AC Pereira, ... Circulation 141 (17), 1371-1383, 2020 | 229 | 2020 |
| Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy SM Hegde, SJ Lester, SD Solomon, M Michels, PM Elliott, SF Nagueh, ... Journal of the American College of Cardiology 78 (25), 2518-2532, 2021 | 191 | 2021 |
| Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure JM Testani, JS Hanberg, S Cheng, V Rao, C Onyebeke, O Laur, A Kula, ... Circulation: Heart Failure 9 (1), e002370, 2016 | 185 | 2016 |
| Genetic and phenotypic landscape of peripartum cardiomyopathy R Goli, J Li, J Brandimarto, LD Levine, V Riis, Q McAfee, S DePalma, ... Circulation 143 (19), 1852-1862, 2021 | 181 | 2021 |
| Update on hypertrophic cardiomyopathy and a guide to the guidelines S Sen-Chowdhry, D Jacoby, JC Moon, WJ McKenna Nature Reviews Cardiology 13 (11), 651-675, 2016 | 178 | 2016 |
| Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy C Fumagalli, N Maurizi, SM Day, EA Ashley, M Michels, SD Colan, ... JAMA cardiology 5 (1), 65-72, 2020 | 153 | 2020 |
iacopo olivottoCardiomyopathy Unit, Careggi University Hospital, FlorenceVerified email at aou-careggi.toscana.it
